Stricturing and Fistulizing Crohn’s Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease

Weizman, Adam V.; Sharma, Robyn; Afzal, Nooran M; Xu, Wei; Walsh, Scott; Stempak, Joanne M.; Nguyen, Geoffrey C.; Croitoru, Ken; Steinhart, A. Hillary; Silverberg, Mark S.

doi:10.1007/s10620-018-5096-2

Cited by 21 publications

(28 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A more recent study shows a much higher incidence at 10.5%, but psoriasiform lesions are more common than psoriasis and have distinctive features. According to current evidence, females, smokers, and patients with fistulising disease appear to be at risk . In addition to anti‐TNF induced psoriasis, psoriasiform and drug‐induced psoriasiform lesions have been well‐recognised.…”

Section: Aims and Methodsmentioning

confidence: 96%

“…A nation‐wide cohort study reported incidence rates of anti‐TNF induced psoriasis in IBD at 0.5% per patient‐year . A more recent study shows a much higher incidence at 10.5%, but psoriasiform lesions are more common than psoriasis and have distinctive features. According to current evidence, females, smokers, and patients with fistulising disease appear to be at risk .…”

Section: Aims and Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Review article: managing the adverse events caused by anti‐TNF therapy in inflammatory bowel disease

Shivaji

Sharratt

Thomas

et al. 2019

Aliment Pharmacol Ther

121

View full text Add to dashboard Cite

Background: Biological therapy is currently widely used to treat IBD. Infliximab, adalimumab and golimumab are currently licensed anti-TNF therapies. Biosimilar anti-TNF monoclonal antibodies are increasingly used. Anti-TNF therapies are widely used and their adverse effects are well characterised, and may cause significant morbidity and mortality in a small proportion of exposed patients. Gastroenterologists need to understand the mechanisms for these effects, recognise these swiftly and manage such events appropriately. Aim:To cover the range of potential adverse reactions as a result of biologic therapy and specifically management of these events. Methods: A Medline and Pubmed search was undertaken. Search terms includedwere "anti-TNF," "infliximab" or "adalimumab" or "golimumab" combined with the keywords "ulcerative colitis" or "Crohn's disease" or "inflammatory bowel disease" and then narrowed to articles containing the keywords "complications," "side effects" or "adverse events" or "safety profile." International guidelines were also reviewed where relevant.Results: Adverse events discussed in this review include infusion reactions, blood disorders and infections (including bacterial, viral, fungal and opportunistic infections) as well as autoimmune, dermatological disorders, cardiac and neurological conditions. Malignancies including solid organ, haematological and those linked to viral disease are discussed. Conclusions:Anti-TNF therapy has wide-ranging effects on the immune system resulting in a spectrum of potential adverse events in a small proportion of patients.Research advances are improving the understanding, recognition and management of these adverse events.

show abstract

Section: Aims and Methodsmentioning

confidence: 96%

Section: Aims and Methodsmentioning

confidence: 99%

Review article: managing the adverse events caused by anti‐TNF therapy in inflammatory bowel disease

Shivaji

Sharratt

Thomas

et al. 2019

Aliment Pharmacol Ther

121

View full text Add to dashboard Cite

show abstract

“…The meta-analysis concluded that women were stronger predictors of sex (OR=1.54) and had a 1.54 times higher incidence of psoriasis than male. Women with IBD are more likely to develop psoriasis induced by TNF antagonist in amount of studies [20,29,32]. Hence it is necessary to pay more attention to the psoriasis inpact on the quality of life and mental health in female patients.…”

Section: Discussionmentioning

confidence: 99%

“…More than 80% of the reported TNF-antagonist-induced psoriasis lesions involved more than 2 sites of body [13,24,25]. According to the literature, the skin lesions of psoriasis induced by TNF-antagonists were mainly distributed in scalp, metacarpal, limbs and skin folds [13,19,29,30].…”

Section: Distribution Of Lesionsmentioning

confidence: 99%

“…Some studies suggest that psoriasis may be a prevalent side effect of TNF-antagonists, also known as class effects [11]. The pathogenesis of psoriasis induced by TNF-antagonists is still not and TH1 cells, resulting in the disruption of cytokine balance in vivo [10], Which can lead to psoriasis [24,29,41], It may be related to IFN induced gene overexpression [22]. There are also a small number of people who believe that IBD patients with Cytokine receptor mutation, which leads to psoriasis [18]; 3) treatment with TNF-antagonists increases the risk of infection, and exposure to infected organisms increases the risk of psoriasis, especially pustular psoriasis [37]; 4) many autoimmune diseases originate at the gene level, TNF-antagonist-induced psoriasis may be associated with the pathogenesis of psoriasis, and patients using TNF-antagonists are more genetic predisposition [42].…”

Section: Pathogenesis Of Psoriasismentioning

confidence: 99%

See 1 more Smart Citation

A systematic review and meta-analysis: Female smokers,even former smokers lead higher incidence of psoriasis in the treatment of inflammatory bowel disease with biological agents.

Yang¹,

Liu²,

Deng

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: At present, infliximab(IFX) and adalimumab(ADA) are the classic drugs for the treatment of moderate-severe inflammatory bowel disease(IBD), which prove effective for the disease control. However, the side effects need to be monitored during the therapy process, especially the paradoxical reaction of the skin system such as psoriasis, which could greatly benefit quality of patients’ life.Aim: In order to describe and analyze TNF-antagonist-induced psoriasis in patients with inflammatory bowel disease from the aspects of incidence, pathogenesis, distribution and type of lesions, prognosis and treatment, the incidence of psoriasis induced by Infliximab (IBD) and Adalimumab (ADA) in the treatment of Inflammatory Bowel Disease Disease (IBD) as well as the relationship between sex, smoking and the incidence of psoriasis were investigated.Methods: Literatures in English language meeting the qualifications on Pubmeb, Embase, Web of Science, Google, and Geenmedical databases were searched . More than two co-authors evaluated the quality of the article and extracted the data respectively. The data obtained were statistically analyzed by statistical software of Revman and Stata.Results: 1) The incidence of psoriasis was higher in ADA Group (OR 0.66, P<0.05, 95% CI (0.52-0.84) ; 2) The incidence of psoriasis was higher in females than in males (OR 1.54, P<0.05, 95% CI (1.27-1.86)) ; 3) Smoking increased the incidence of psoriasis (OR 1.79, P<0.01, 95% CI (1.42-2.24); 4) Psoriasis is mainly distributed in the Scalp, Palmoplantar, skin folds and limbs, and often occurs in the genital organs, the pathogenesis of which is not completely clear; the interval of medication is more than one year, and the interval of medication using IFX is longer than that of ADA Group; most cases can be relieved by local hormone, phototherapy or systemic hormone therapy without changing the strategy of biological agents.Conclusion: The incidence of psoriasis induced by TNF-antagonists is higher in many autoimmune diseases. The frequency of reported in inflammatory bowel disease is higher than other autoimmune diseases, and the safety of ADA Treatment for IBD is higher than that of IFX The incidence of psoriasis is higher in women than in men; the incidence of psoriasis is significantly higher in smokers / ex-smokers than in non-smokers. The interval of drug use of TNF-antagonists may be a predictive factor for the prevention and treatment of psoriasis, and there are differences among different kinds of TNF-antagonists. Change of therapeutic strategy of TNF-antagonists is not recommended in the event of psoriasis.

show abstract

Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis

Murphy

Cohen

Vesely

et al. 2022

Journal of the American Academy of Dermatology

101

View full text Add to dashboard Cite

Stricturing and Fistulizing Crohn’s Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease

Cited by 21 publications

References 25 publications

Review article: managing the adverse events caused by anti‐TNF therapy in inflammatory bowel disease

Review article: managing the adverse events caused by anti‐TNF therapy in inflammatory bowel disease

A systematic review and meta-analysis: Female smokers,even former smokers lead higher incidence of psoriasis in the treatment of inflammatory bowel disease with biological agents.

Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis

Contact Info

Product

Resources

About